Pharmacokinetics of Ambroxol Sustained Release (Mucosolvan^® Retard) Compared with Other Formulations in Healthy Volunteers.

ABSTRACT:

Introduction

Ambroxol is used in the treatment of acute and chronic respiratory conditions characterized by abnormal mucus secretion and impaired mucus transport and is available in a variety of formulations. This study aimed to compare the steady-state (SS) pharmacokinetic characteristics of extended-release (ER) 75-mg retard capsules with two immediate-release (IR) formulations (60-mg effervescent tablets and 30-mg tablets) over a 24-h period.

Methods

An open-label, randomized, three-period, six-sequence crossover study was conducted in healthy volunteers aged 18-45 years who had a normal body mass index. The test (ER 75-mg retard capsule once daily) and reference treatments (half of IR 60-mg effervescent tablet twice daily or 30-mg IR tablet twice daily) were administered

SUBMITTER: Ollier C 

PROVIDER: S-EPMC7229136 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature